APIXABAN (ELIQUIS®) - Thrombosis Canada
Acute treatment of DVT or PE: 10 mg BID for 7 days, followed by 5 mg BID. Apixaban should not be used in patients with a CrCl <25mL/min, women who are pregnant or breast-feeding, patients with active cancer, or patients with severe liver disease. Continued prevention of recurrent DVT and PE: After at least 6 months of treatment, ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- prior authorization anticoagulants eliquis apixaban
- annex i summary of product characteristics
- apixaban eliquis thrombosis canada
- deep vein thrombosis dvt treatment
- choosing the right dose of eliquis apixaban for your
- anticoagulation therapeutic management adults only
- drug utilisation sub committee dusc pbs
- australian public assessment report forapixaban
- anticoagulation management health
- anticoagulation management